← 返回

CAR-T 细胞疗法治疗中枢神经系统肿瘤

英文原题:CAR-T Cell Therapy for Central Nervous System Tumors.

查看英文原题

CAR-T Cell Therapy for Central Nervous System Tumors.

PubMed 2026/01/01(内容时间) Methods Mol Biol

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

嵌合抗原受体(CAR)T细胞疗法已成为中枢神经系统(CNS)肿瘤的一种有前景的免疫疗法,尽管存在血脑屏障(BBB)和免疫抑制性肿瘤微环境(TME)带来的独特生物学障碍。本章全面综述了CAR设计的演变、使用慢病毒载体(LVVs)的基因递送方法以及针对CNS肿瘤的临床应用。我们讨论了CAR-T 细胞疗法治疗CNS肿瘤的当前问题,同时重点介绍了关于新CAR设计和新型递送方法以克服这些问题的策略。

展开英文摘要原文

Chimeric antigen receptor (CAR) T cell therapy has emerged as a promising immunotherapy for central nervous system (CNS) tumors, despite the unique biological barriers posed by the blood-brain barrier (BBB) and immunosuppressive tumor microenvironment (TME). This chapter comprehensively reviews the evolution of CAR designs, gene delivery methods using lentiviral vectors (LVVs), and clinical applications for CNS tumors.

We discuss current issues in CAR-T cell therapy for CNS tumors, while highlighting the strategies about new CAR designs and novel delivery methods to overcome these issues.

论文信息

作者
Ohno M、Fujita M
单位
Department of Neurosurgery, Aichi Cancer Center, Nagoya, Japan. m.ono@aichi-cc.jp.Japan
文献类型
综述 · 非美国政府资助研究
期刊
Methods in molecular biology (Clifton, N.J.)2026
原文标识
PubMed 41273656 · DOI 10.1007/978-1-0716-4807-0_21